masthead-publications

Categories

Filter by Topics

ADCC Gene Alteration ALK Angiogenesis Anti-TNF Alpha Therapy Apoptosis Asthma Autocrine Signaling Autoimmune Disorder Biofluid Biology of neoplasia Biomarker Analysis Biomarker Discovery Biomarker Validation Biomarkers Bladder Cancer Brain Breast Cancer Breast milk Cardiovascular Disease CDKN2A mutation Cells Cerebrospinal Fluid Childhood Atopic Dermatitis Chronic Obstructive Pulmonary Disease Circulating miRNAs cMET Colorectal cancer Comparison study Core Needle Biopsy COVID-19 Custom mRNA Cytokines Developmental Immunotherapy Developmental Therapeutics Diabetes Differential Expression Differential Gene Expression Analysis DLBCL Drug Response Drug Safety Drug Targets Drug-induced Liver Injury Efficacy EGFR Muatations EMT Encephalophy Epstein-Barr ERBB3 Esophageal Cancer Exosomes Extracellular Vesicles Fabry Disease Feasibility FFPE FGF Ligand Trap FGFR Fibrous Tumors Follicular lymphoma Gene Expression Profiling Gene Fusions Gene Signature Analysis Genetic Polymorphism Genitourinary cancer Glioblastoma Tumors Head and Neck Cancer Heart HER2 Histone Deacetylase Inhibitors HLA-E HPV HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq Custom Assays HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq DLBCL-COO-CE-IVD HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immune Response Panel HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq Lymphoma Panel HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq Mouse mRNA Tumor Response Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq PATH Assay HTG EdgeSeq Path Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq System HTG EdgeSeq System Oncology Biomarker Panel HTG EdgSeq Immuno-Oncology Assay Immune Checkpoint Inhibitors Immune Related Genes Immune Response Immune Tolerance Immune-related Colitis Immuno-Oncology Immunotherapy Inflammation Juvenile Arthritis Kidney Liposarcoma Liquid Biopsy Liver Lung Lupus Lymph Node Metastasis Lymphoma Mechanism of Action Melanoma Mesothelioma MET Method Comparison Microenvironment miRNA Molecular Characterization Mouse mRNA custom mTOR pathway Multiple Myeloma Muscle Mutations MYC NAFLD Nash and Fibrosis Natural Killer Cells Neoantigens Neuroendocrine Tumor Neurologic non-Hodgkin Lymphoma Novel Therapeutic Targets NTRK1 Oesophageal Adenocarcinoma Oncology Oral Cancer Osteoclast Ovarian cancer Pancreas Paralysis Parkinson's Disease Pathogenesis Pathway Analysis Patient Stratification PAXgene PBMCs PCA Cell Lines PD-1 PD-L1 PIK3CA mutation Placenta Plasma Platform Comparison Predictive Modeling Programmed cell death protein 1 Progression free-survival Prostate Prostate Cancer qNPA qPCR Radioimmunotherapy Rearrangements Renal Disease Response rate RET Reveal Rheumatoid Arthritis Risk Score ROS1 safety Sarcoma Serum Signaling Inhibitors Signaling Pathways Signature Validation Signatures Sinonasal Carcinoma Skin SPECS Lung Consortium Squamous cell carcinoma Sub-typing Surveillance Survival Outcomes Survival plots Synovial Fluid Technology Comparison Therapeutic Response Therapeutic targets TMB Toxicity TP53 mutation Translational Medicine Transplantation Treatment Outcome Treatment Stratification Treatment Targets Tumor Biology Tumor Heterogeneity Tumor Immunobiology Tumor infiltrating lymphocytes tumor microenvironment Urine Urothelial carcinoma VEGFR Xenograft Tissue

2021

Plk1 expression & efficacy of Palbociclib in advanced hormonal receptor-positive breast cancer patients from PEARL study (GEICAM 2012-03)

Guerrero-Zotano, A., et al. Plk1 expression & efficacy of Palbociclib in advanced hormonal receptor-positive breast cancer patients from PEARL study (GEICAM 2012-03). Cancer Res February 15 2021 (81) (4 Supplement) PS2-01; DOI: 10.1158/1538-7445.SABCS20-PS2-01

View External Link

2020

Tumor Microenvironment Associated with complete Response to Tislelizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma Reveals a Potentially Different Mechanism of Action

Song, Y., et al. Tumor Microenvironment Associated with complete Response to Tislelizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma Reveals a Potentially Different Mechanism of Action. Blood Journal 2020. NOV 5 136(S1):10-11.

View External Link

78 T-Cell, MHC I, and tumor intrinsic gene signatures predict clinical benefit and resistance to tislelizumab monotherapy in pretreated PD-L1+ urothelial carcinoma

Ye, D., et al. 78 T-Cell, MHC I, and tumor intrinsic gene signatures predict clinical benefit and resistance to tislelizumab monotherapy in pretreated PD-L1+ urothelial carcinoma. Journal for Immunotherapy of Cancer 2020(8)S3: A1-A959- pre-print

Download pdf 1.0MB

2019

Reliable Gene Expression Profiling from Small and Hematoxylin and Eosin-Stained Clinical Formalin-Fixed, Paraffin-Embedded Specimens Using the HTG EdgeSeq Platform

Qi, Z., et al. Reliable Gene Expression Profiling from Small and Hematoxylin and Eosin-Stained Clinical Formalin-Fixed, Paraffin-Embedded Specimens Using the HTG EdgeSeq Platform. J Mol Diagn. 2019 Sep;21(5):796-807.

View External Link

2018

Detection of a MicroRNA molecular signature of ultraviolet radiation in the superficial regions of melanocytic nevi on sun-exposed skin

Bell, A. et al, Detection of a MicroRNA molecular signature of ultraviolet radiation in the superficial regions of melanocytic nevi on sun-exposed skin. Modern Pathology 2018 Jun 28. doi: 10.1038/s41379-018-0088-5. [Epub ahead of print].

Download pdf 18.9MB
View External Link

Page last updated April 14, 2021